SU5607 CAS NO.186611-52-9

1.we are direct manufacturer and we have 7 years experience in this aera.
2.we can provide competitive price for every customer and guarantee the quality of our goods.
3.Specials are possible when client's order is big enough, including the discount policy;
4.we promise we will return your money if our product don't have effect.
5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;
6. Our customers may buy our products again after they use our sample.

In stock ,>98% purity with low price. If you need HNMR\HPLC,please contact us!

IC261, also known as SU5607, is a potent and selective CK1 inhibitor. IC261 triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. At low micromolar concentrations IC261 inhibits cytokinesis causing a transient mitotic arrest. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ and Wnt/β-catenin independent inhibition of mitotic spindle formation. IC261 binds to tubulin with an affinity similar to colchicine and is a potent inhibitor of microtubule polymerization. This activity accounts for many of the diverse biological effects of IC261 and, most importantly, for its selective cancer cell killing. 

Tianjin Kailiqi Biopharma Technology Co., Ltd, is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. Our company has strong R&D ability and production experience to provide the customers new APIs. We specialize in developing innovative processes for the synthesis of a wide range of products. We also undertake custom synthesis and contract manufacturing.if you are interest in,pls contact with me,we also have Lab,specifical in some hard synthesis.